The global GLP-1 market, valued at USD 47.74 billion in 2024, is projected to expand at a compound annual growth rate of 10.9% between 2025 and 2034, reflecting one of the most significant growth trajectories in the pharmaceutical sector. This surge underscores the rising demand for glucagon-like peptide-1 receptor agonists, driven by escalating diabetes prevalence, growing recognition of obesity as a public health crisis, and broadening clinical applications beyond glycemic control. Regional dynamics, however, tell a more nuanced story of how regulatory frameworks, reimbursement strategies, and healthcare infrastructure shape market penetration strategies. North America, Europe, and Asia Pacific stand out as key pillars, each contributing distinctly to the expansion of this fast-evolving therapeutic domain.
North America dominates the GLP-1 landscape, with the United States accounting for the lion’s share of global revenue. The U.S. Food and Drug Administration’s (FDA) accelerated approval pathways for semaglutide, liraglutide, and newer dual-action molecules have stimulated rapid uptake among patients and prescribers. In addition, the Centers for Disease Control and Prevention (CDC) reports that over 38 million Americans live with diabetes, while n